Clinical and biological activity of rituximab in the treatment of pemphigus

被引：5

作者：

Bohelay, Gerome ^{[1
,2
]}

Caux, Frederic ^{[1
,2
]}

Musette, Philippe ^{[1
,2
]}

机构：

[1] Grp Hosp Paris Seine St Denis, AP HP, Dept Dermatol, Bobigny, France

[2] INSERM UMR1125, Bobigny, France

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 01期

关键词：

B-cell depletion therapy; CD20; monoclonal antibody; pemphigus; rituximab; B-CELL DEPLETION; MONOCLONAL-ANTIBODY RITUXIMAB; VULGARIS FOLLOWING RITUXIMAB; LOW-DOSE RITUXIMAB; RHEUMATOID-ARTHRITIS; ADJUVANT RITUXIMAB; SINGLE-CENTER; INTRALESIONAL RITUXIMAB; COMBINATION THERAPY; ANTI-CD20; ANTIBODY;

D O I：

10.2217/imt-2020-0189

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

B-cells are major effector cells in autoimmunity since they differentiate into plasmocytes that produce pathogenic auto-antibody such as anti-desmoglein antibodies in pemphigus patients. Major advances were obtained using whole B-cell depleting therapies including anti-CD20 antibodies in refractory pemphigus patients that lead to rituximab approval in pemphigus patients in EU and USA. This review summarizes the data supporting the efficacy of rituximab in pemphigus and provides an overview of the reported immunological changes underlying its therapeutic action. Short and long-term remission in pemphigus is explained by the removal of autoreactive B-cells involved in the production of pathogenic IgG auto-antibodies and by enhancement of the appearance of regulatory B-cells that could maintain long term immune tolerance.

引用

页码：35 / 53

页数：20

共 128 条

[21] Concurrent Cytomegalovirus and Herpes Simplex Virus Infection in Pemphigus Vulgaris Treated with Rituximab and Prednisolone [J].

Chiu, Hsien-Yi ;

Chang, Chia-Ying ;

Hsiao, Cheng-Hsiang ;

Wang, Li-Fang .

ACTA DERMATO-VENEREOLOGICA, 2013, 93 (02) :200-201

[22] Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab [J].

Cho, Alice ;

Bradley, Bridget ;

Kauffman, Robert ;

Priyamvada, Lalita ;

Kovalenkov, Yevgeniy ;

Feldman, Ron ;

Wrammert, Jens .

JCI INSIGHT, 2017, 2 (12)

[23] Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities [J].

Cho, H. H. ;

Jin, S. -P. ;

Chung, J. H. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (02) :186-191

[24] First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus [J].

Cho, Yung-Tsu ;

Lee, Fang-Yu ;

Chu, Chia-Yu ;

Wang, Li-Fang .

ACTA DERMATO-VENEREOLOGICA, 2014, 94 (04) :472-473

[25] Therapy with rituximab for autoimmune pemphigus: Results from a single-center observational study on 42 cases with long-term follow-up [J].

Cianchini, Giuseppe ;

Lupi, Francesca ;

Masini, Cinzia ;

Corona, Rosamaria ;

Puddu, Pietro ;

De Pita, Ornella .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (04) :617-622

[26] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[27] Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response [J].

Colliou, Natacha ;

Picard, Damien ;

Caillot, Frederique ;

Calbo, Sebastien ;

Le Corre, Stephanie ;

Lim, Annick ;

Lemercier, Brigitte ;

Le Mauff, Brigitte ;

Maho-Vaillant, Maud ;

Jacquot, Serge ;

Bedane, Christophe ;

Bernard, Philippe ;

Caux, Frederic ;

Prost, Catherine ;

Delaporte, Emmanuel ;

Doutre, Marie-Sylvie ;

Dreno, Brigitte ;

Franck, Nathalie ;

Ingen-Housz-Oro, Saskia ;

Chosidow, Olivier ;

Pauwels, Christine ;

Picard, Catherine ;

Roujeau, Jean-Claude ;

Sigal, Michele ;

Tancrede-Bohin, Emmanuelle ;

Templier, Isabelle ;

Eming, Ruediger ;

Hertl, Michael ;

D'Incan, Michel ;

Joly, Pascal ;

Musette, Philippe .

SCIENCE TRANSLATIONAL MEDICINE, 2013, 5 (175)

[28] Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris [J].

Daneshpazhooh, M. ;

Kamyab, K. ;

Kalantari, M. -S. ;

Balighi, K. ;

Naraghi, Z. S. ;

Shamohammadi, S. ;

Mortazavizadeh, S. M. -A. ;

Ramezani, A. ;

Chams-Davatchi, C. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (01) :41-47

[29] Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission [J].

Daneshpazhooh, Maryam ;

Sedigh, Vahid Zafarmand ;

Balighi, Kamran ;

Hosseini, S. Hamed ;

Ramezani, Ali ;

Kalantari, Mohammad-Sadegh ;

Ghandi, Narges ;

Ghiasi, Maryam ;

Nikoo, Azita ;

Chams-Davatchi, Cheyda .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (06) :1160-1165

[30] Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature [J].

de Sena Nogueira Maehara, L. ;

Huizinga, J. ;

Jonkman, M. F. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) :1420-1423

← 1 2 3 4 5 6 7 8 9 10 →